Q-omics provides the consensus-scored WNT8A profile across patient tissues and cancer cell-line models. WNT8A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, WNT8A is differentially expressed in 4, with the highest sampling consensus in UCEC. Additionally, WNT8A RNA expression shows 10,788 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, UCEC, and TGCT as cancer lineages where WNT8A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WNT8A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WNT8A survival associations across molecular data types. WNT8A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WNT8A RNA expression–survival associations across cancer types. High WNT8A expression shows unfavorable associations in UVM, READ, GBM and OV, but favorable associations in LUSC and ESCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for WNT8A RNA expression.
This table summarizes WNT8A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4, while mass-spec protein shows differences in 4. The strongest signals are observed in BRCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for WNT8A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WNT8A shows lower tumor expression in UCEC and BRCA and higher tumor expression in KIRC and THCA. The UCEC box plot shows higher WNT8A RNA expression in normal versus tumor tissue (log2 FC = −0.210, t-test p = .031).
This table shows molecular features associated with WNT8A in patient tissues and cancer cell lines. In patient samples, WNT8A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, WNT8A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
